The authors found that I2PP2A is overexpressed in prostate tumor cells and that while the expression of the PP2A catalytic subunit did not change comparing prostate epithelial cells and prostate cancer cells the tyrosine phosphorylation of the subunit was increased in tumor cells, indicative of reduced PP2A activity. Ceramide treatment killed prostate tumor cells but not normal prostate epithelial cells. Ceramide treatment disrupted the association between PP2A and I2PP2A and it blocked I2PP2A function in terms of inhibiting PP2A catalytic activity to dephosphorylate and decrease accumulation of the oncogene c-Myc. Overexpression of I2PP2A increased the c-Myc expression and ceramide treatment decreased c-Myc levels in I2PP2A-GFP expresing cells Collectively the data argued for a positive role of I2PP2A for inhibition of PP2A activity toward c-Myc.

PP2A is a well-described tumor suppressor that can reduce the activities of many pro-oncogenic signal transduction pathways. One of the initial observations of ceramide on cell signaling was inhibition of, e.g., ERK1/2 signaling, which would lead to reduced growth and a lower apoptotic threshold. The present manuscript expands upon this notion with regard to PP2A, I2PP2A, and the regulation of c-Myc. The transcription factor c-Myc can promote growth as well as regulate the cyclin kinase inhibitor p21/the cell cycle and also cause tumor cell death; these effects on tumor cell biology can be context dependent. In the present manuscript the authors went on to show that in at least one of the prostate cancer lines ceramide/I2PP2A signaling also regulated histone acetylation. Understanding how ceramide and I2PP2A regulate prostate cancer biology, tumor growth, gene expression and the apoptotic threshold in this tumor types will no doubt be the subject of a future study by these authors.
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